Abstract
Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Current Drug Safety
Title:Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects
Volume: 9 Issue: 2
Author(s): George F. Lasker, Fikret Halis and Ahmet Gokce
Affiliation:
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Abstract: Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Export Options
About this article
Cite this article as:
Lasker F. George, Halis Fikret and Gokce Ahmet, Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects, Current Drug Safety 2014; 9 (2) . https://dx.doi.org/10.2174/1574886309666140120095846
DOI https://dx.doi.org/10.2174/1574886309666140120095846 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Different Soil Enrichments on the Physicochemical and Antioxidant Potential of Red and White Calyx from Roselle (Hibiscus sabdariffa L.)
Current Nutrition & Food Science Editorial [Hot Topic: Inflammation in Atherosclerosis: Current Therapeutic Approaches (Executive Guest Editor: Dimitris Tousoulis)]
Current Pharmaceutical Design Type 2 Diabetes: An Atherothrombotic Syndrome
Current Molecular Medicine Non-cholesterol Sterols in the Diagnosis and Treatment of Dyslipidemias: A Review
Current Medicinal Chemistry Heart Rate as a Therapeutic Target in Angina Pectoris
Current Pharmaceutical Design Bioactive Proteins and Peptides from Soybeans
Recent Patents on Food, Nutrition & Agriculture Salvaging the Ischemic Heart: Gi-Coupled Receptors in Mast Cells Activate a PKCε/ALDH2 Pathway Providing Anti-RAS Cardioprotection
Current Medicinal Chemistry The Influence of Obese Insulin-Resistance on the Outcome of the Ischemia/Reperfusion Insult to the Heart
Current Medicinal Chemistry Severe Coagulation Disorder and Thrombocytopenia Associated with Tigecycline – Case Report and Review of Literature
Current Drug Safety Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Drug-Drug Interactions Associated with Antiplatelet Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure
Current Pharmaceutical Design Potential Therapeutic Applications of Metal Compounds Directed Towards Hypoxic Tissues
Current Medicinal Chemistry Can Lipoprotein-associated Phospholipase A<sub>2</sub> be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?
Current Cardiology Reviews Cardiac MRI in Infiltrative Disorders: A Concise Review
Current Cardiology Reviews Evaluating 3D-printed Bolus Compared to Conventional Bolus Types Used in External Beam Radiation Therapy
Current Medical Imaging Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature
Current Diabetes Reviews